

From: Do, Yu  
Sent: Friday, February 19, 2016 10:12 AM  
To: dmyers@malvernconsultinggroup.com  
Subject: Information Request (Response Due by Friday, February 26, 2016):  
Original BLA, BL 125590/0, Immune Globulin Intravenous (Human) [RI-002], ADMA Biologics, Inc.

Importance: High

Dear Ms. Myers:

We are reviewing your original July 31, 2015, submission to BLA 125590 for Immune Globulin Intravenous (Human). We are providing the following comments and request additional information to continue our review:

1. Please provide the following information or documents for the Agency to review:

\* Analysis of particles that appeared at 12 months for Bivigam's lot (b) (4). In addition, please indicate if the particles identified for this lot is comparable to those of RI-002's Lot (b) (4).

\* Investigation report for Bivigam's Lot (b) (4) regarding visual appearance OOS at 12 months (i.e., Biotest Investigation Number FR-2013-18 INV 9004: Visual particles in BIVIGAM vials (b) (4)).

\* Stability testing and/or study performed for Lot (b) (4).

2. Please provide one vial (50 ml) per lot of the following (b) (4) final products for (b) (4) testing: (b) (4). The testing will be conducted for research purposes only and not for lot release. Please use the following address for shipping:

FDA/CBER/OBRR  
Attn: Yonggang Wang/Nancy Eller/Dr. Dorothy Scott  
Building 52, Room 4140  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: (240) 402-8236

Please notify Yonggang Wang (Yonggang.Wang@fda.hhs.gov), Dorothy Scott (Dorothy.Scott@fda.hhs.gov), and Nancy Eller (Nancy.Eller@fda.hhs.gov) when the samples are being shipped. Also, please include the tracking number in this notification.

The review of this submission is ongoing and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file by February 26, 2016, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is July 30, 2016.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or Yu.Do@fda.hhs.gov if you have any questions.

Sincerely,

Yu Do, M.S.  
Regulatory Project Manager  
FDA/OMPT/CBER/OBRR/RPMS  
(240) 402-8343  
yu.do@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."